Notice on Convening the 2026 Annual General Meeting
Filed with SSE · · 10 pages · Chinese
Earlier from InnoCare Pharma
- InnoCare Releases 2026 Q1 Results: Strong Revenue Growth and Sustained Profitability
- Preclinical Data of Novel B7-H3 ADC ICP-B794 Unveiled at 2026 AACR, Demonstrating Superior Anti-Tumor Activity and Safety
- Announcement on Convening the Q1 2026 Performance Briefing
- InnoCare Releases 2025 Results and Business Highlights, Achieving First Annual Profit
- Announcement on Convening the 2025 Annual Performance Briefing
Later from InnoCare Pharma
- InnoCare Announces First Patient Dosed in Phase III Trial of Orelabrutinib for SLE
- Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% Scale
- InnoCare Announces Approval of Clinical Trial of Novel CDH7 targeted ADC ICP-B208 in China
- InnoCare Announces Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Sjögren's Syndrome in China
- InnoCare Announce First Subject Dosed in Phase 1 Clinical Trial of ICP-054, a Novel Potentially Best-in-Class Oral IL-17AA/AF Inhibitor
Follow InnoCare Pharma into a list and get an email when it puts out news.
Follow InnoCare Pharma